Did you miss this March article?
Generalized pustular psoriasis (GPP) is a serious and unpredictable skin condition with limited treatment options. The Effisayil 1 trial evaluated spesolimab, a monoclonal antibody targeting interleukin-36 signaling, as a potential therapy for acute GPP flares.
The study faced unique challenges, but findings suggest spesolimab may offer rapid improvement for patients experiencing a flare. This article explores the trial’s outcomes, the impact on treatment strategies, and what dermatologists need to know about this emerging option.
J Drugs Dermatol. 2025;24(3):242-245. doi:10.36849/JDD.8322
